微信直播

Prof. J. Jan B. van Lanschot:食管癌治疗的研究进展分享

Published at: 2015年第1卷第S1期

刘黎畅
关键词:

编者按:由上海市防癌抗癌事业发展基金会、AME出版社主办的“胸怀大治——2017 胸部肿瘤规范化治疗上海国际论坛”于2017年10月19日到21日顺利召开。本次会议就肺癌和食管癌领域的热点问题展开充分的研讨,强调胸部肿瘤规范化治疗的理念。国内外胸外科专家在此次会议中进行深入的交流和学习,共飨学术饕餮盛宴。受大会主席陈海泉教授邀请,在世界食管癌临床研究领域享有盛誉的荷兰Erasmus Medical Centre and ErasmusUniversity的 J. Jan B. van Lanschot教授参加了本次论坛,AME出版社也有幸邀请其接受采访。

 

人物聚焦:Prof. J. Jan B. van Lanschot

 

J.J.B. (Jan) van Lanschot (1953) is currently Professor of Surgery at the Erasmus Medical Centre and Erasmus University, Rotterdam, the Netherlands. 

 

He has held visiting Professorships at the Universities of Adelaide, Barcelona, Hong Kong, Los Angeles and Stockholm. 

 

He has held a variety of managerial and executive appointments both locally and (inter-)nationally including programme director for Surgical Training at the AMC in Amsterdam, chairman of the Dutch Society of GI Surgery, board member of the Dutch Society of Surgery, chairman of European Digestive Surgery, chairman of the European Society for Diseases of the Esophagus, and secretary of the European Surgical Association. 

 

He is editorial board member of several scientific journals, including British Journal of Surgery, Digestive Surgery, Diseases of the Esophagus and World Journal of Surgery. 

 

He is honorary member of the Dutch Society of GI Surgery, the Polish Society of Surgical Oncology, the Royal College of Surgeons of Edinburgh, the German Society of General and Visceral Surgery and the Brazilian College of Digestive Surgery. He received named honorary medals of the Dutch Society of Gastroenterology and the Swedish Society of Medicine and Surgery.

 

His research interests currently lie mainly in the field of oesophago-gastric surgery and particularly upper GI cancers. He has published more than 300 peer reviewed articles and more than 50 books / book chapters.

 

图1. J. Jan B. van Lanschot教授和编辑合影

J. Jan B. van Lanschot教授在肿瘤外科领域工作30余年,致力于食管癌和上消化道癌症的研究,做出了很多杰出贡献。van Lanschot教授2002年在新英格兰医学杂志(N Engl J Med.)发表了“经膈裂空对比经胸食管癌切除的研究”,同时也是“Cross”研究的重要参与者,在国际上享有盛誉。采访中,van Lanschot教授向我们分享了自己如何平衡忙碌的工作、生活和学术研究的经验,也讲述了目前肥胖症并发上消化道恶性肿瘤患者在诊断和治疗中所面临的挑战。对于新辅助治疗在食管癌中的应用价值,经验丰富的van Lanschot教授通过对比日本、中国、欧洲等国家、地区新辅助治疗的发展现状,认为新辅助治疗手段是未来食管癌治疗的必然趋势。

在复旦大学附属肿瘤医院观看了食管癌手术视频演示后,van Lanschot教授对中国医生的腔镜手术操作、开放手术操作的规范和熟练给予了高度的认可和称赞,并认为规范化治疗是提高癌症手术疗效的关键。会议间歇van Lanschot教授还与复旦大学附属肿瘤医院的病理科及放疗科专家进行了座谈,深入交流了多学科治疗的开展,并对肿瘤医院领先的胸部肿瘤多学科综合诊疗工作模式非常地赞赏。

作为一名老师,是van Lanschot教授职业生涯中最为自豪的事情。他很享受带领学生开展临床试验研究,探索未知的领域,“看到我的学生们能够在世界各地的机构、组织担任要职,为医学发展做出自己的努力和贡献,我感到非常的开心和欣慰。”

更多精彩内容分享,欢迎观看视频:

 

 
 

采访问题

 

1. We have known that you have hold a variety of managerial and executive appointments both locally and internationally, and you have published over 300 peer reviewed articles. How can you balance the academic research and daily work?    

2. Would you introduce the development of Uniportal VATS in Europe?

3. What clinical challenges are you facing with in upper gastrointestinal malignancies after bariatric surgery?

4. What role does lymphadenectomy play in Esophageal Cancer?

5. What’s the progress of Neoadjuvant Chemoradio-therapy Surgery for Esophageal Cancer?

6. When you look back to your career as a surgeon and director, what is the thing that has made you proudest or most memorable?

 

 

 

采写编辑:刘黎畅,AME Publishing Company

视频剪辑:麦雪芳,AME Publishing Company

comments powered by Disqus

附件